Monte Rosa Therapeutics, Inc. (GLUE), a developer of novel molecular glue degrader-based medicines, said that it has priced its underwritten public offering of 11.125 million shares at $24 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1.375 million shares at $23.999 per pre-funded warrant.
Monte Rosa also granted the underwriters a 30-day option to purchase up to an additional 1.875 million shares at $24 per share.
The company anticipates gross proceeds of around $300 million from the offering, excluding any exercise of the underwriters' option to purchase additional shares.
All of the shares and pre-funded warrants are to be sold by Monte Rosa.
The offering is expected to close on or about January 12.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.